Adherence to inhaled corticosteroids (ICS) in asthma is suboptimal. Patients may rely more on their short-acting beta-agonist (SABA) to control symptoms, which may increase their risk of exacerbations and uncontrolled asthma. Our objective is to describe ICS adherence and SABA use among Dutch primary care patients with asthma, and how these are related to exacerbations and self-reported asthma control. Patients aged ≥12 years diagnosed with asthma who received ≥2 inhalation medication prescriptions in 2016 were selected from the Nivel Primary Care Database. ICS adherence (continuous measure of medication availability), SABA use (number of prescriptions), exacerbations (short courses of oral corticosteroids with daily dose ≥20 mg), and asthm...
Purpose: Many patients with asthma still have insufficient disease control, despite the availability...
Purpose: Many patients with asthma still have insufficient disease control, despite the availability...
Funding This study is funded by General Practitioners Research Institute and AstraZeneca Netherlands...
Adherence to inhaled corticosteroids (ICS) in asthma is suboptimal. Patients may rely more on their ...
Adherence to inhaled corticosteroids (ICS) in asthma is suboptimal. Patients may rely more on their ...
Adherence to inhaled corticosteroids (ICS) in asthma is suboptimal. Patients may rely more on their ...
Adherence to inhaled corticosteroids (ICS) in asthma is suboptimal. Patients may rely more on their ...
Adherence to inhaled corticosteroids (ICS) in asthma is suboptimal. Patients may rely more on their ...
Adherence to inhaled corticosteroids (ICS) in asthma is suboptimal. Patients may rely more on their ...
Adherence to inhaled corticosteroids (ICS) in asthma is suboptimal. Patients may rely more on their ...
Adherence to inhaled corticosteroids (ICS) in asthma is suboptimal. Patients may rely more on their ...
ABSTRACT: Introduction The relationship between inhaled corticosteroids (ICS) adherence, short-acti...
Introduction The relationship between inhaled corticosteroids (ICS) adherence, short-acting beta ago...
Purpose: Many patients with asthma still have insufficient disease control, despite the availability...
Purpose: Many patients with asthma still have insufficient disease control, despite the availability...
Purpose: Many patients with asthma still have insufficient disease control, despite the availability...
Purpose: Many patients with asthma still have insufficient disease control, despite the availability...
Funding This study is funded by General Practitioners Research Institute and AstraZeneca Netherlands...
Adherence to inhaled corticosteroids (ICS) in asthma is suboptimal. Patients may rely more on their ...
Adherence to inhaled corticosteroids (ICS) in asthma is suboptimal. Patients may rely more on their ...
Adherence to inhaled corticosteroids (ICS) in asthma is suboptimal. Patients may rely more on their ...
Adherence to inhaled corticosteroids (ICS) in asthma is suboptimal. Patients may rely more on their ...
Adherence to inhaled corticosteroids (ICS) in asthma is suboptimal. Patients may rely more on their ...
Adherence to inhaled corticosteroids (ICS) in asthma is suboptimal. Patients may rely more on their ...
Adherence to inhaled corticosteroids (ICS) in asthma is suboptimal. Patients may rely more on their ...
Adherence to inhaled corticosteroids (ICS) in asthma is suboptimal. Patients may rely more on their ...
ABSTRACT: Introduction The relationship between inhaled corticosteroids (ICS) adherence, short-acti...
Introduction The relationship between inhaled corticosteroids (ICS) adherence, short-acting beta ago...
Purpose: Many patients with asthma still have insufficient disease control, despite the availability...
Purpose: Many patients with asthma still have insufficient disease control, despite the availability...
Purpose: Many patients with asthma still have insufficient disease control, despite the availability...
Purpose: Many patients with asthma still have insufficient disease control, despite the availability...
Funding This study is funded by General Practitioners Research Institute and AstraZeneca Netherlands...